Personalis (NASDAQ:PSNL) Shares Up 6.8% - What's Next?

Key Points

• Shares rose 6.8% to $6.43 on Monday, but trading volume was just 363,257 shares—about a 75% decline from the average session volume, suggesting the move occurred on light trading.
• Analyst sentiment is mixed-but-leaning-positive: five Buys, one Hold and one Sell give an average rating of "Moderate Buy" with an average price target of $11.50; several firms raised targets to $12–$13 while Morgan Stanley cut its target to $10.
• Personalis is a clinical-stage genomics company with negative profitability (net margin -116.69%, negative ROE) despite a slight quarterly beat (EPS -$0.26 vs. -$0.31; revenue $17.35M); analysts forecast -1.4 EPS for the year and institutional investors own about 61.9% of the stock.

Personalis, Inc. (NASDAQ:PSNL - Get Free Report)'s share price shot up 6.8% during mid-day trading on Monday . The stock traded as high as $6.56 and last traded at $6.4310. 363,257 shares traded hands during mid-day trading, a decline of 75% from the average session volume of 1,436,175 shares. The stock had previously closed at $6.02.

Analyst Upgrades and Downgrades

Several brokerages have issued reports on PSNL. Morgan Stanley decreased their target price on shares of Personalis from $11.00 to $10.00 and set an "equal weight" rating for the company in a report on Thursday, March 5th. Weiss Ratings reaffirmed a "sell (d-)" rating on shares of Personalis in a report on Thursday, January 22nd. Needham & Company LLC lifted their target price on shares of Personalis from $10.00 to $12.00 and gave the stock a "buy" rating in a report on Friday, February 27th. BTIG Research lifted their target price on shares of Personalis from $12.00 to $13.00 and gave the stock a "buy" rating in a report on Wednesday, February 11th. Finally, Guggenheim lifted their price target on shares of Personalis from $12.00 to $13.00 and gave the stock a "buy" rating in a research note on Monday, January 26th. Five research analysts have rated the stock with a Buy rating, one has assigned a Hold rating and one has given a Sell rating to the company. According to MarketBeat.com, the stock has an average rating of "Moderate Buy" and an average price target of $11.50.

Personalis Price Performance

The firm's 50-day moving average is $7.73 and its 200-day moving average is $8.42. The company has a market capitalization of $668.59 million, a P/E ratio of -6.98 and a beta of 2.20.

Personalis (NASDAQ:PSNL - Get Free Report) last announced its earnings results on Thursday, February 26th. The company reported ($0.26) earnings per share (EPS) for the quarter, beating the consensus estimate of ($0.31) by $0.05. The company had revenue of $17.35 million during the quarter, compared to analyst estimates of $17.12 million. Personalis had a negative net margin of 116.69% and a negative return on equity of 39.13%. As a group, analysts forecast that Personalis, Inc. will post -1.4 EPS for the current fiscal year.

Institutional Trading of Personalis

Several large investors have recently added to or reduced their stakes in the business. Caitong International Asset Management Co. Ltd lifted its holdings in Personalis by 76.1% during the fourth quarter. Caitong International Asset Management Co. Ltd now owns 3,423 shares of the company's stock valued at $27,000 after purchasing an additional 1,479 shares in the last quarter. T. Rowe Price Investment Management Inc. lifted its holdings in Personalis by 273.9% during the fourth quarter. T. Rowe Price Investment Management Inc. now owns 10,780,290 shares of the company's stock valued at $85,812,000 after purchasing an additional 7,896,714 shares in the last quarter. Oracle Investment Management Inc. lifted its holdings in Personalis by 47.9% during the fourth quarter. Oracle Investment Management Inc. now owns 339,343 shares of the company's stock valued at $2,701,000 after purchasing an additional 109,908 shares in the last quarter. First Manhattan CO. LLC. purchased a new position in Personalis during the fourth quarter valued at approximately $2,976,000. Finally, Guggenheim Capital LLC purchased a new position in Personalis during the fourth quarter valued at approximately $108,000. 61.91% of the stock is currently owned by institutional investors.

Personalis Company Profile

Personalis, Inc NASDAQ: PSNL is a clinical‐stage genomics company that develops and markets advanced next‐generation sequencing (NGS) services and assays designed to accelerate precision medicine. The Company's core offering is the ImmunoID NeXT™ Platform, which combines comprehensive tumor profiling—including whole exome, transcriptome, and T‐cell receptor sequencing—with proprietary bioinformatics to identify biomarkers and guide immuno‐oncology research. Personalis serves biopharmaceutical companies, academic institutions, and clinical research organizations seeking in‐depth insights into cancer, autoimmune diseases and other complex conditions.

In addition to its flagship ImmunoID NeXT™ Platform, Personalis offers a suite of customizable sequencing assays for biomarker discovery, clinical trial support and companion diagnostic development.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.